Prestige Biopharma was initially established in Singapore. Since its establishment in 2015, Singapore Research Center has been focusing on Prestige Biopharma Group’s biosimilar pipeline R&D.
Singapore Research Center covers 12 biosimilar pipeline products from its early stage of cell line development to phase 1-3 clinical study. Prestige’s rich portfolio of biosimilars in various stages including HD201 trastuzumab in EU EMA’s MAA review, HD204 bevacizumab in global Phase 3, PBP1502 adalimumab in Phase 1 and others, is aimed to provide affordable quality medicines to those who need.
To date, Prestige has developed biosimilars of high quality and strong cost competitiveness in expedited development programmes, with the aim of enhancing patient access to affordable treatments for critical diseases areas.
Prestige is also expanding its discovery technologies based on an open innovation platform targeting next-generation biotherapeutics, creating a paradigm-shift in the bio-industry through innovative R&D efforts.
Innovative Discovery Center (IDC) was established in 2021 for innovative drug discovery R&D.
IDC focuses on diverse first-in-class antibody biologics discovery starting from 9 bispecific antibody projects based on PBP’s proprietary oncology therapeutic targets, PAUF and CTHRC1. Next generation vaccines and bioinformatics will be developed in IDC for current and potential future pandemics.
IDC is target to build a global-scale R&D center with a total area of 31,300m2 and it is scheduled for completion by 2023.
Advanced Research Center (ARC) was established in Boston, known as the largest bio cluster in USA. Boston is also home to major universities and venture companies, including global pharmaceutical & biotech companies and research institutes.
ARC leads Prestige Biopharma Group’s advanced analytical research and frontier research in new targeted therapy and manages global regulatory affairs as well.